我国淋巴瘤随机对照临床试验的现况分析

Present Status of Randomized Controlled Clinical Trials for Lymphoma in China

[目的]分析我国淋巴瘤治疗领域随机对照临床试验研究现状。[方法]选择＂万方数据库＂（1989~2012）、＂中国知网＂（1979~2013）,以＂淋巴瘤＂、＂随机＂、＂对照＂、＂病人＂或＂病例＂或＂患者＂为检索词,对2000年1月至2011年12月间期刊发表的随机对照临床试验文献进行检索。分析文献的发表时间、研究者所在地区及机构、文献的疾病分布、文献来源期刊等。[结果]有效文献120篇,2000~2005年37篇（30.8%）,2006~2011年83篇（69.2%）;文献产出地主要分布于东南沿海地区;研究内容集中于非霍奇金淋巴瘤的治疗,特别是利妥昔单抗及CHOP方案的应用。[结论]我国淋巴瘤治疗性随机对照临床试验研究方向与数量随时间呈增多趋势,然而仍存在地区分布不均、研究质量不高等问题。

[Purpose] To evaluate the current situation of randomized controlled clinical trials for lymphoma in China.[Methods] The randomized controlled clinical trials published in the journals from January 2000 to December 2011 were searched by using ＂lymphoma＂,＂random＂,＂control＂and ＂patient＂ or ＂case＂ as the search words from ＂WANFANG data＂（1989~2012） and ＂CNKI.NET＂（1979 ~2013） database. The publication years,researchers＇ regions and institutions,diseases distribution and source journals of these literatures were analyzed. [Results] A total of 120valid literatures were enrolled,including 37（30.8%） articles from 2000 to 2005,83（69.2%） articles from 2006 to 2011. Literatures output mainly were distributed in the southeast coastal areas. Research content focused on the treatment of non-Hodgkin＇s lymphoma,especially the applications of rituximab and CHOP regimen.[Conclusions] Lymphoma therapeutic randomized controlled trials in China have the same research direction with international,the literature numbers showed an increasing trend over time.However,there are still some problems such as uneven areas distribution,low research quality,etc.